Business Wire

Amadis Leverages Nexo Standards to Simplify Global Payment Acceptance

29.9.2020 14:55:00 EEST | Business Wire | Press release

Share

Amadis, a payment software and consulting services provider, today announced a streamlined path for North American and international merchants to migrate to the nexo global payment standard, the most comprehensive set of global payment acceptance protocols on the market today. By integrating nexo’s messaging protocols, standards and specifications into its Arkos universal payments acceptance software, Amadis provides “plug-and-play” universal payment software that enables customers to quickly accept new payment types, independent of equipment, technology or geography.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005023/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Amadis targets interoperability in global payments :a forefront concern for today's evolving payments space. (Photo: Business Wire)

Amadis has helped a diverse range of banking, retail and transport customers deploy nexo-based applications, enabling customers to future-proof their payment systems, while lowering development time and accelerating time to market. With Amadis’ Arkos product, an EMV middleware that manages all the card acceptance processing, customers can rapidly migrate to nexo and vastly reduce their custom development requirements, enabling companies to substantially reduce time to market, risks and costs for each unique payment solution implementation. Arkos can manage any type of equipment (standalone, PINPads, unattended, mobile) and devices while:

  • Integrating US processing rules (debit network selection; low value payments)
  • Providing central management and reporting
  • Meeting M-TIP, ADVT Pre-certified EMV requirements

“By editing the Amadis Arkos software using nexo protocols, we ensure our clients have the same common interoperable interface and protocol across the globe that breeds innovation at the point of contact,” said Emmanuel Haydont, CEO, and co-founder of Amadis. “By using nexo protocols, we help our customers drastically reduce time to market and cost of ownership, while enabling them to free themselves from unnecessary technical dependencies and provide a pathway that better future-proofs merchants as payments continue to evolve.”

nexo standards is the international association enabling global interoperability in payment acceptance. Its membership is expanding rapidly across continents, with members from several countries including the United States, Canada, China, India, Japan, Russia, and Saudi Arabia, further cementing the global interest in its standards and its truly international reach.

Unlike proprietary solutions that lock companies into using proprietary host interfaces, terminal management systems (TMS), platforms or operating in a certain geography, nexo is an open standard that guarantees multiple interoperabilities: cross border, platform, host, market segment and others. nexo standards enables companies to innovate on top of its specifications and protocols, removing both the significant complexity from the technical integration as well as the implementation challenges companies face as they expand acceptance of new payment types from devices in new markets. The nexo association provides open standards and protocols that guarantee cross-border interoperability.

“Market demand for nexo standards is higher than ever before. In response, active members such as Amadis are making significant progress in their deployment and adoption strategies,” comments Jacques Soussana, Secretary-General at nexo standards. “With the combination of our specifications, protocols, implementation guidelines, collaborative working groups, and testing and certification support, we are providing members with the tools to build and validate their solutions, fast-tracking their path to deployment. The global adoption of nexo standards is fast becoming a reality.”

Amadis’ global customers require payment acceptance solutions that are secure and ensure optimized operations, while allowing for best management of future-proofing needs in the near and long-term. nexo standards is the international association enabling global interoperability in payment acceptance. With the recent global stresses the economy and industries have faced, it has become imperative that solution providers seek out standards such as nexo that allow businesses to operate more efficiently and expand globally.

*EMV ® is a registered trademark in the U.S. and other countries and an unregistered trademark elsewhere. The EMV trademark is owned by EMVCo, LLC

About Amadis

Amadis is a privately-held division of Maxim Integrated. Amadis is a leader in payment software technology, with its software running on more than 10 million devices worldwide. The company provides state-of-the-art software editing and development solutions for global merchants, payment device manufacturers and service providers. Amadis provides merchants with the industry’s broadest range of payment processing options using custom or commercially available technology, independent of hardware or geography. The company brings an elite, experienced software team to the industry and enables solutions for international merchants in over 23 countries. Learn more at www.amadis.ca.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Vivian Shen
Amadis
vsh@amadis.ca

Media:
David Finkelstein
The DFI Group
david@thedfigroup.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye